Sonoma Retained Earnings vs Current Deferred Revenue Analysis

SNOA Stock

USD 2.93 0.08 2.81%

Sonoma Pharmaceuticals financial indicator trend analysis is much more than just breaking down Sonoma Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sonoma Pharmaceuticals is a good investment. Please check the relationship between Sonoma Pharmaceuticals Retained Earnings and its Current Deferred Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.

Retained Earnings vs Current Deferred Revenue

Retained Earnings vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sonoma Pharmaceuticals Retained Earnings account and Current Deferred Revenue. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Sonoma Pharmaceuticals' Retained Earnings and Current Deferred Revenue is 0.48. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Sonoma Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Sonoma Pharmaceuticals' Retained Earnings and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Sonoma Pharmaceuticals are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Retained Earnings i.e., Sonoma Pharmaceuticals' Retained Earnings and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.48

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Sonoma Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sonoma Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.At present, Sonoma Pharmaceuticals' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 3.5 M, whereas Discontinued Operations is forecasted to decline to about 568.6 K.

	2021	2022	2023	2024 (projected)
Gross Profit	4.0M	4.5M	4.7M	5.1M
Total Revenue	12.6M	13.3M	12.7M	11.3M

Gross Profit Total Revenue

Sonoma Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Total Current Assets	Other Assets	Other Stockholder Equity	Total Liab	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Current Deferred Revenue	Retained Earnings	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Inventory	Other Current Assets	Property Plant And Equipment Gross	Short Term Debt
Total Assets		0.86	-0.73	0.74	0.74	0.2	0.88	0.32	0.69	0.22	-0.49	0.06	0.06	-0.34	-0.19	-0.57	0.21	0.41	0.57	0.25	-0.68	-0.04	0.45	0.27	0.0	-0.53
Total Stockholder Equity	0.86		-0.86	0.79	0.79	0.32	0.76	0.31	0.41	-0.3	-0.72	0.29	-0.23	-0.07	-0.33	-0.26	0.21	0.36	0.64	0.11	-0.39	-0.46	0.39	0.0	-0.16	-0.79
Net Debt	-0.73	-0.86		-0.97	-0.97	-0.06	-0.74	-0.17	-0.22	0.28	0.52	-0.3	0.2	0.01	0.09	0.03	-0.07	-0.14	-0.52	0.19	0.27	0.42	-0.14	0.14	0.2	0.58
Cash	0.74	0.79	-0.97		1.0	0.03	0.79	0.18	0.27	-0.14	-0.33	0.21	-0.17	-0.06	-0.07	-0.12	0.13	0.05	0.55	-0.16	-0.37	-0.26	0.12	-0.09	-0.24	-0.43
Cash And Short Term Investments	0.74	0.79	-0.97	1.0		0.03	0.79	0.18	0.27	-0.14	-0.33	0.21	-0.17	-0.06	-0.07	-0.12	0.13	0.05	0.55	-0.16	-0.37	-0.26	0.12	-0.09	-0.24	-0.43
Common Stock Shares Outstanding	0.2	0.32	-0.06	0.03	0.03		0.28	0.19	0.36	-0.24	-0.23	0.28	-0.14	0.03	-0.51	-0.29	0.55	-0.13	0.45	0.82	-0.25	-0.38	0.45	-0.23	-0.14	-0.28
Total Current Assets	0.88	0.76	-0.74	0.79	0.79	0.28		0.49	0.74	0.18	-0.31	-0.16	-0.2	-0.32	-0.44	-0.64	0.36	-0.08	0.71	0.3	-0.66	0.07	0.61	0.35	0.08	-0.31
Other Assets	0.32	0.31	-0.17	0.18	0.18	0.19	0.49		0.26	0.03	-0.16	-0.55	-0.31	0.11	-0.56	-0.41	0.15	-0.22	0.67	0.12	0.0	0.31	0.69	0.61	0.63	0.06
Other Stockholder Equity	0.69	0.41	-0.22	0.27	0.27	0.36	0.74	0.26		0.5	-0.19	-0.29	-0.08	-0.7	-0.46	-0.91	0.31	-0.02	0.39	0.62	-0.9	0.31	0.69	0.48	0.14	-0.16
Total Liab	0.22	-0.3	0.28	-0.14	-0.14	-0.24	0.18	0.03	0.5		0.46	-0.45	0.56	-0.49	0.28	-0.56	-0.01	0.08	-0.15	0.25	-0.51	0.81	0.1	0.52	0.31	0.54
Short Long Term Debt Total	-0.49	-0.72	0.52	-0.33	-0.33	-0.23	-0.31	-0.16	-0.19	0.46		-0.3	0.2	0.14	0.21	0.09	0.17	-0.46	-0.16	0.0	0.11	0.56	-0.25	-0.01	-0.06	0.89
Other Current Liab	0.06	0.29	-0.3	0.21	0.21	0.28	-0.16	-0.55	-0.29	-0.45	-0.3		0.3	0.18	0.38	0.51	-0.03	0.43	0.0	0.02	0.09	-0.84	-0.37	-0.87	-0.69	-0.49
Total Current Liabilities	0.06	-0.23	0.2	-0.17	-0.17	-0.14	-0.2	-0.31	-0.08	0.56	0.2	0.3		0.02	0.75	0.11	-0.03	0.51	-0.31	0.09	-0.01	0.13	-0.33	-0.11	0.0	0.23
Property Plant And Equipment Net	-0.34	-0.07	0.01	-0.06	-0.06	0.03	-0.32	0.11	-0.7	-0.49	0.14	0.18	0.02		0.03	0.68	0.25	-0.02	0.12	-0.29	0.81	-0.32	-0.25	-0.26	0.05	0.07
Current Deferred Revenue	-0.19	-0.33	0.09	-0.07	-0.07	-0.51	-0.44	-0.56	-0.46	0.28	0.21	0.38	0.75	0.03		0.48	-0.45	0.43	-0.58	-0.43	0.21	0.01	-0.77	-0.38	-0.21	0.22
Retained Earnings	-0.57	-0.26	0.03	-0.12	-0.12	-0.29	-0.64	-0.41	-0.91	-0.56	0.09	0.51	0.11	0.68	0.48		-0.27	0.08	-0.32	-0.59	0.83	-0.52	-0.64	-0.67	-0.25	0.02
Accounts Payable	0.21	0.21	-0.07	0.13	0.13	0.55	0.36	0.15	0.31	-0.01	0.17	-0.03	-0.03	0.25	-0.45	-0.27		-0.26	0.46	0.54	-0.17	-0.08	0.39	0.07	-0.14	0.0
Non Current Assets Total	0.41	0.36	-0.14	0.05	0.05	-0.13	-0.08	-0.22	-0.02	0.08	-0.46	0.43	0.51	-0.02	0.43	0.08	-0.26		-0.15	-0.09	-0.09	-0.24	-0.22	-0.11	-0.13	-0.52
Non Currrent Assets Other	0.57	0.64	-0.52	0.55	0.55	0.45	0.71	0.67	0.39	-0.15	-0.16	0.0	-0.31	0.12	-0.58	-0.32	0.46	-0.15		0.29	-0.25	-0.14	0.72	0.1	-0.03	-0.21
Net Receivables	0.25	0.11	0.19	-0.16	-0.16	0.82	0.3	0.12	0.62	0.25	0.0	0.02	0.09	-0.29	-0.43	-0.59	0.54	-0.09	0.29		-0.51	0.05	0.53	0.06	-0.03	-0.04
Common Stock Total Equity	-0.68	-0.39	0.27	-0.37	-0.37	-0.25	-0.66	0.0	-0.9	-0.51	0.11	0.09	-0.01	0.81	0.21	0.83	-0.17	-0.09	-0.25	-0.51		-0.25	-0.38	-0.26	0.17	0.18
Non Current Liabilities Total	-0.04	-0.46	0.42	-0.26	-0.26	-0.38	0.07	0.31	0.31	0.81	0.56	-0.84	0.13	-0.32	0.01	-0.52	-0.08	-0.24	-0.14	0.05	-0.25		0.14	0.74	0.52	0.69
Inventory	0.45	0.39	-0.14	0.12	0.12	0.45	0.61	0.69	0.69	0.1	-0.25	-0.37	-0.33	-0.25	-0.77	-0.64	0.39	-0.22	0.72	0.53	-0.38	0.14		0.5	0.36	-0.12
Other Current Assets	0.27	0.0	0.14	-0.09	-0.09	-0.23	0.35	0.61	0.48	0.52	-0.01	-0.87	-0.11	-0.26	-0.38	-0.67	0.07	-0.11	0.1	0.06	-0.26	0.74	0.5		0.74	0.2
Property Plant And Equipment Gross	0.0	-0.16	0.2	-0.24	-0.24	-0.14	0.08	0.63	0.14	0.31	-0.06	-0.69	0.0	0.05	-0.21	-0.25	-0.14	-0.13	-0.03	-0.03	0.17	0.52	0.36	0.74		0.29
Short Term Debt	-0.53	-0.79	0.58	-0.43	-0.43	-0.28	-0.31	0.06	-0.16	0.54	0.89	-0.49	0.23	0.07	0.22	0.02	0.0	-0.52	-0.21	-0.04	0.18	0.69	-0.12	0.2	0.29

Click cells to compare fundamentals

Sonoma Pharmaceuticals Account Relationship Matchups

Sonoma Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	14.6M	15.0M	18.8M	16.2M	14.7M	15.3M
Total Stockholder Equity	8.7M	5.4M	8.7M	8.0M	6.1M	8.7M
Net Debt	(2.2M)	(1.5M)	(6.0M)	(3.0M)	(2.5M)	(2.6M)
Cash	3.7M	4.2M	7.4M	3.8M	3.1M	5.3M
Cash And Short Term Investments	3.7M	4.2M	7.4M	3.8M	3.1M	5.3M
Common Stock Shares Outstanding	1.5M	99.8K	132.7K	169.7K	454.5K	262.8K
Liabilities And Stockholders Equity	14.6M	15.0M	18.8M	16.2M	14.7M	15.3M
Total Current Assets	12.4M	13.0M	16.4M	13.8M	12.5M	12.6M
Other Assets	850K	875K	1.5M	1.5M	1.8M	1.8M
Other Stockholder Equity	186.6M	189.2M	197.4M	200.9M	203.2M	148.5M
Total Liab	5.9M	9.6M	10.1M	8.3M	8.6M	6.9M
Short Long Term Debt Total	1.5M	2.7M	1.4M	849K	608K	1.2M
Other Current Liab	1.8M	(2.6M)	(2.0M)	(2.5M)	(2.8M)	(2.7M)
Total Current Liabilities	4.9M	4.1M	5.8M	3.7M	3.7M	3.7M
Property Plant And Equipment Net	1.3M	1.1M	879K	906K	651K	958.7K
Current Deferred Revenue	273K	319K	1.3M	160K	478K	673.3K
Retained Earnings	(172.2M)	(179.3M)	(184.4M)	(189.5M)	(194.3M)	(204.1M)
Accounts Payable	2.1M	1.8M	1.6M	841K	607K	1.1M
Non Current Assets Total	2.2M	2.0M	2.4M	2.4M	2.2M	2.9M
Non Currrent Assets Other	850K	875K	707K	578K	396K	584.7K
Net Receivables	5.4M	2.8M	2.4M	2.6M	2.9M	2.3M
Non Current Liabilities Total	991K	5.5M	4.3M	4.5M	4.9M	5.1M
Inventory	2.2M	2.5M	2.7M	2.9M	2.7M	1.7M
Other Current Assets	428K	3.4M	4.0M	4.5M	3.8M	4.0M
Property Plant And Equipment Gross	1.3M	1.1M	2.6M	2.9M	3.0M	1.7M
Accumulated Other Comprehensive Income	(5.6M)	(4.6M)	(4.3M)	(3.4M)	(2.7M)	(2.9M)
Short Term Debt	732K	1.1M	1.1M	943K	719K	781.0K
Property Plant Equipment	365K	1.1M	879K	906K	815.4K	906.4K
Other Liab	245K	3.7M	4.0M	4.4M	5.0M	5.3M
Retained Earnings Total Equity	(157.4M)	(169.2M)	(172.2M)	(179.3M)	(161.3M)	(169.4M)
Deferred Long Term Liab	443K	356K	245K	229K	263.4K	382.5K
Net Tangible Assets	8.7M	5.4M	8.7M	8.0M	7.2M	9.0M
Capital Surpluse	176.7M	184.1M	186.6M	189.2M	217.6M	189.6M
Short Long Term Debt	481K	596K	808K	431K	323K	366.2K
Capital Lease Obligations	997K	769K	559K	418K	285K	478.6K
Net Invested Capital	9.2M	7.3M	9.5M	8.4M	6.5M	7.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Sonoma Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonoma Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonoma Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonoma Pharmaceuticals Stock:

How To Invest In Sonoma

Details

Is Sonoma Stock a good investment?

Details

What is Sonoma Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.

You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.99)

Revenue Per Share

20.967

Quarterly Revenue Growth

(0.01)

Return On Assets

(0.20)

Return On Equity

(0.75)

The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sonoma Retained Earnings vs Current Deferred Revenue Analysis

Retained Earnings vs Current Deferred Revenue

Retained Earnings vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Retained Earnings

Current Deferred Revenue

Sonoma Pharmaceuticals fundamental ratios Correlations

Sonoma Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Sonoma Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Short Term Debt	+ 0.89	Short Long Term Debt Total
Total Current Assets	+ 0.88	Total Assets
Total Stockholder Equity	+ 0.86	Total Assets
Common Stock Total Equity	+ 0.83	Retained Earnings
Net Receivables	+ 0.82	Common Stock Shares Outstanding

Cash And Short Term Investments	- 0.97	Net Debt
Cash	- 0.97	Net Debt
Retained Earnings	- 0.91	Other Stockholder Equity
Common Stock Total Equity	- 0.9	Other Stockholder Equity
Other Current Assets	- 0.87	Other Current Liab
Net Debt	- 0.86	Total Stockholder Equity